Phase I investigator-initiated study of the safety of MTC001 in patients with chronic ischemic heart failure

Machino Takeshi0 sites6 target enrollmentMay 10, 2021

Overview

No summary available.

Registry

who.int

Start Date

May 10, 2021

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Sex

All

Sponsor

Machino Takeshi

•1\)Patients diagnosed with heart failure with old myocardial infarction as the underlying disease.
•2\)Patients with chronic ischemic heart failure with heart failure stage C and NYHA II or III (medical history of myocardial infarction at the time of informed consent).
•3\) Left ventricular ejection fraction (LVEF) 40% or less by echocardiography.
•4\)Patients who are not eligible for CRT or who show less than 5% LVEF improvement after 90 days or more of treatment.

•1\)Diabetic patients who have difficulty controlling their condition (HbA1c over 8\.5%).
•2\)Patients with congenital enzyme abnormality and muscle disease.
•3\)Patients with active autoimmune disease
•4\)Patients with active malignant tumor. However, patients who have been diagnosed with complete remission and have not relapsed for 5 years or more (10 years or more for breast cancer) can be registered if it can be confirmed by systemic screening by CT / MRI etc. that there is no recurrence.
•5\)Female patients who are pregnant or may become pregnant.
•6\)Estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1\.73 square meter, or serum creatinine is 3\.0 mg/dL or more.
•7\)Hematocrit less than 25%
•8\)Patients receiving other gene therapy, cell therapy, etc. for severe heart failure within 2 years
•9\)Patients who have difficulty walking due to reasons other than heart failure (orthopedic diseases, etc.).
•10\)Patients with a history of serious allergies (contrast media allergy, status asthmaticus, anaphylactic shock, etc.).

Not specified